Skip to Content

Hai T. Tran, Pharm.D

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Pharmacy Associate Director, Department of Pharmacy Research, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1400 Holcombe Blvd
Unit Number: 432
Houston, TX 77030

Education & Training

Degree-Granting Education

1994 University of Kentucky, College of Pharmacy, Lexington, KY, PHARMD, Doctor of Pharmacy
1989 Temple University, School of Pharmacy, Philadelphia, PA, B.S. Pharmacy, Pharmacy
1986 University of Dayton, Dayton, OH, Pre-Pharmacy, Pharmacy

Selected Publications

Peer-Reviewed Original Research Articles

1. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran HT, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-90, 1/2013. e-Pub 10/2012. PMCID: PMC3567921.
2. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827-37, 8/2012. e-Pub 7/2012. PMID: 22759480.
3. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 5/2012. e-Pub 10/2011. PMCID: PMC3893000.
4. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma. J Thorac Oncol 6(12):2104-11, 12/2011. e-Pub 9/2011. PMID: 21892101.
5. Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT, Yan S, Dewhirst MW, Kunnamakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diet on plasma levels of NF-{kappa}B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila). e-Pub 7/2011. PMID: 21764858.
6. De Groot JF, Piao Y, Tran HT, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 17(14):4872-81, 7/2011. e-Pub 6/2011. PMCID: PMC3139700.
7. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 6/2011. e-Pub 1/2010. PMID: 20094773.
8. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein Jr GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery 1(1):44-53, 6/2011. e-Pub 4/2011.
9. Brooks HD, Glisson BS, Bekele BN, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117(10):2112-9, 5/2011. e-Pub 11/2010. PMID: 21523723.
10. Berlin JM, Leonard AD, Pham TT, Sano D, Marcano DC, Yan S, Fiorentino S, Milas ZL, Kosynkin DV, Price BK, Lucente-Schultz RM, Wen X, Raso MG, Craig SL, Tran HT, Myers JN, Tour JM. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified Paclitaxel. ACS Nano 4(8):4621-36, 8/2010. PMID: 20681596.
11. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 6/2010. e-Pub 6/2010. PMID: 20530716.
12. Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70(6):2171-9, 3/2010. e-Pub 3/2010. PMID: 20215520.
13. Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 28(2):193-201, 1/2010. e-Pub 11/2009. PMID: 19949019.
14. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 1/2010. e-Pub 12/2009. PMCID: PMC2815707.
15. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RN, Tsao AS, Tran HT, Dang TP. VeriStrat(r) classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer, 12/2009. e-Pub 12/2009. PMID: 20036440.
16. Choi K, Ahn YH, Gibbons DL, Tran HT, Creighton CJ, Girard L, Minna JD, Qin FX, Kurie JM. Distinct biological roles for the notch ligands Jagged-1 and Jagges-2. J Biol Chem 284(26):17766-74, 6/2009. e-Pub 4/2009. PMCID: PMC2719415.
17. Hanrahan EO, Kies MS, Glisson BS, Khuri FI, Feng L, Tran HT, Ginsbery LE, Truong MT, Hong WK, Kim Es. A Phase II Study of Lonafarnib (SCH66336) in Patients with Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol, 5/2009. PMID: 19433965.
18. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran HT, Pezzuto JM, Moriarty RM, Hong WK. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97(22):1695-9, 11/2005. PMID: 16288123.
19. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892-9, 9/2005. PMID: 16043829.
20. Abramson DH, Frank CM, Chantada GL, de Totah AB, de Pifano IT, Ramirez GT, Gomez RT, Fandino AT, Tran HT, Madden TJ, Dunkel IJ. Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet 20(1):31-6, 3/1999. PMID: 10415463.
21. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 116(9):1209-12, 9/1998. PMID: 9747681.
22. Worth LL, Tran HT, Madden T, Przepiorka D, Chan KW, Jaffe N. High-dose busulfan, thiotepa, and cyclophosphamide: an effective preparative regimen for stem cell transplantation for myeloid malignancies in children. Journal of Pediatric Hematology/Oncology 20(4):375, 8/1998.
23. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15(5):1796-802, 5/1997. PMID: 9164187.

Book Chapters

1. Tran HT, Tett T. Therapeutic drug monitoring in hematopoietic stem cell transplant recipients. In: Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd. Ed(s) in Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK. Cambridge Press: Cambridge, England, 505-514, 2004.

Last updated: 5/28/2015